3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
8
Carcinoma, Merkel Cell
6
Neoplasm Metastasis
5
Carcinoma, Transitional Cell
5
Breast Neoplasms
5
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Penile Squamous Cell Carcinoma (PSCC)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
23
fludarabine
14
Rituximab
14
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
Doxorubicin
7
pirtobrutinib
6
Vincristine
6
Prednisone
6
zanubrutinib
4
polatuzumab vedotin
4
obinutuzumab
4
Nivolumab
4
Etoposide
4
Dexamethasone
4
Biopsy
4
tazemetostat
3
tafasitamab
3
pembrolizumab
3
ibrutinib
3
glofitamab
3
fludarabine phosphate
3
acalabrutinib
3
Immunotherapy, Adoptive
3
Bendamustine Hydrochloride
3
venetoclax
2
pomalidomide
2
etoposide phosphate
2
cemiplimab
2
Prednisolone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
avelumab
×
90 days
×
Clear all
No trials found.